山東新華製藥股份(00719.HK)擬斥1億元參與設立北方健康
格隆匯6月23日丨山東新華製藥股份(00719.HK)宣佈,公司擬與聯仁健康醫療大數據科技股份有限公司(聯仁健康)、銀豐新百健康大數據股份有限公司、山東發展投資控股集團有限公司、山東能源醫療健康投資有限公司、山東省財金髮展有限公司、山東福田花雨珠寶有限公司、山東魯抗醫藥股份有限公司、山大地緯軟件股份有限公司、山東國惠基金管理有限公司、山東眾陽健康科技集團有限公司以及山東步長製藥股份有限公司(統稱為眾投資方)就於中國成立一家有限責任公司,簽訂一份投資協議。
據悉,聯仁健康於2019年11月在上海自由貿易區張江註冊成立,是中國移動發起的大數據公司。聯仁健康擬在中國設立一家有限責任公司(註冊資本為人民幣25億元),以運營一所專注於健康醫療相關領域的大數據中心,就此擬與眾投資方簽署投資協議。上述擬成立公司的名稱目前擬定為北方健康醫療大數據科技有限公司。該公司名稱將以主管市場監督管理局核准登記的內容為準。其中公司認購金額為1億元人民幣,股權比例佔4.00%。
公司稱,北方健康擬成為經營健康醫療大數據業務的產業集團,在實現山東省互聯互通的基礎上,預期逐步匯聚中國北方地區人口的健康醫療數據。透過簽訂投資協議,公司將可取得健康醫療大數據,預期有利於公司產品研發、臨牀發展及電商業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.